TrialsgrambetaRCTs are beautiful

ISAR-REACT 5

2019

Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes

In 4,018 patients with acute coronary syndromes managed invasively, prasugrel reduced death, MI or stroke at one year compared with ticagrelor.

Result

Efficacy: Death, MI or stroke at 12 monthsHR 1.36

Below 1 favours ticagrelor, above 1 favours prasugrel.

Event rates
Absolute difference
2.4 points

The absolute difference is derived from the event rates.

Also reported: Major bleeding similar.

Original publication
Subtopic
Antiplatelets
Design
Investigator-initiated, open-label RCT
Relevance
Important: one of several pillars.
Source
Schüpke S, et al. N Engl J Med. 2019;381(16):1524-1534.doi 10.1056/NEJMoa1908973

Discussion & critique

Open-label design and higher ticagrelor discontinuation drew criticism. Nonetheless shifted ESC preference towards prasugrel in NSTE-ACS without pre-treatment.

Discussed in podcasts